217 related articles for article (PubMed ID: 10418979)
1. An estrogen receptor basis for raloxifene action in bone.
Bryant HU; Glasebrook AL; Yang NN; Sato M
J Steroid Biochem Mol Biol; 1999; 69(1-6):37-44. PubMed ID: 10418979
[TBL] [Abstract][Full Text] [Related]
2. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone.
Willson TM; Norris JD; Wagner BL; Asplin I; Baer P; Brown HR; Jones SA; Henke B; Sauls H; Wolfe S; Morris DC; McDonnell DP
Endocrinology; 1997 Sep; 138(9):3901-11. PubMed ID: 9275080
[TBL] [Abstract][Full Text] [Related]
3. Time-dependent changes in biochemical bone markers and serum cholesterol in ovariectomized rats: effects of raloxifene HCl, tamoxifen, estrogen, and alendronate.
Frolik CA; Bryant HU; Black EC; Magee DE; Chandrasekhar S
Bone; 1996 Jun; 18(6):621-7. PubMed ID: 8806005
[TBL] [Abstract][Full Text] [Related]
4. Selective estrogen receptor modulators: an alternative to hormone replacement therapy.
Bryant HU; Dere WH
Proc Soc Exp Biol Med; 1998 Jan; 217(1):45-52. PubMed ID: 9421206
[TBL] [Abstract][Full Text] [Related]
5. [Estrogen receptor and selective estrogen receptor modulators (SERMs)].
Shioi A; Nishizawa Y
Nihon Rinsho; 1999 May; 57(5):1199-207. PubMed ID: 10361456
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacology of conformationally restricted raloxifene analogues: highly potent selective estrogen receptor modulators.
Grese TA; Pennington LD; Sluka JP; Adrian MD; Cole HW; Fuson TR; Magee DE; Phillips DL; Rowley ER; Shetler PK; Short LL; Venugopalan M; Yang NN; Sato M; Glasebrook AL; Bryant HU
J Med Chem; 1998 Apr; 41(8):1272-83. PubMed ID: 9548817
[TBL] [Abstract][Full Text] [Related]
7. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo.
Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU
J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314
[TBL] [Abstract][Full Text] [Related]
8. Raloxifene, tamoxifen, nafoxidine, or estrogen effects on reproductive and nonreproductive tissues in ovariectomized rats.
Sato M; Rippy MK; Bryant HU
FASEB J; 1996 Jun; 10(8):905-12. PubMed ID: 8666168
[TBL] [Abstract][Full Text] [Related]
9. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro.
Taranta A; Brama M; Teti A; De luca V; Scandurra R; Spera G; Agnusdei D; Termine JD; Migliaccio S
Bone; 2002 Feb; 30(2):368-76. PubMed ID: 11856644
[TBL] [Abstract][Full Text] [Related]
10. Raloxifene: a selective estrogen receptor modulator.
Scott JA; Da Camara CC; Early JE
Am Fam Physician; 1999 Sep; 60(4):1131-9. PubMed ID: 10507743
[TBL] [Abstract][Full Text] [Related]
11. Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance.
Yang NN; Bryant HU; Hardikar S; Sato M; Galvin RJ; Glasebrook AL; Termine JD
Endocrinology; 1996 May; 137(5):2075-84. PubMed ID: 8612550
[TBL] [Abstract][Full Text] [Related]
12. Distinct mechanisms of action of selective estrogen receptor modulators in breast and osteoblastic cells.
Nuttall ME; Stroup GB; Fisher PW; Nadeau DP; Gowen M; Suva LJ
Am J Physiol Cell Physiol; 2000 Nov; 279(5):C1550-7. PubMed ID: 11029302
[TBL] [Abstract][Full Text] [Related]
13. Tissue selective action of tamoxifen methiodide, raloxifene and tamoxifen on creatine kinase B activity in vitro and in vivo.
Sömjen D; Waisman A; Kaye AM
J Steroid Biochem Mol Biol; 1996 Dec; 59(5-6):389-96. PubMed ID: 9010344
[TBL] [Abstract][Full Text] [Related]
14. Clinical effects of raloxifene hydrochloride in women.
Khovidhunkit W; Shoback DM
Ann Intern Med; 1999 Mar; 130(5):431-9. PubMed ID: 10068418
[TBL] [Abstract][Full Text] [Related]
15. Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.
Black LJ; Sato M; Rowley ER; Magee DE; Bekele A; Williams DC; Cullinan GJ; Bendele R; Kauffman RF; Bensch WR
J Clin Invest; 1994 Jan; 93(1):63-9. PubMed ID: 8282823
[TBL] [Abstract][Full Text] [Related]
16. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing.
Buelke-Sam J; Bryant HU; Francis PC
Reprod Toxicol; 1998; 12(3):217-21. PubMed ID: 9628546
[TBL] [Abstract][Full Text] [Related]
17. Molecular determinants of tissue selectivity in estrogen receptor modulators.
Grese TA; Sluka JP; Bryant HU; Cullinan GJ; Glasebrook AL; Jones CD; Matsumoto K; Palkowitz AD; Sato M; Termine JD; Winter MA; Yang NN; Dodge JA
Proc Natl Acad Sci U S A; 1997 Dec; 94(25):14105-10. PubMed ID: 9391160
[TBL] [Abstract][Full Text] [Related]
18. Structure-activity relationships of selective estrogen receptor modulators: modifications to the 2-arylbenzothiophene core of raloxifene.
Grese TA; Cho S; Finley DR; Godfrey AG; Jones CD; Lugar CW; Martin MJ; Matsumoto K; Pennington LD; Winter MA; Adrian MD; Cole HW; Magee DE; Phillips DL; Rowley ER; Short LL; Glasebrook AL; Bryant HU
J Med Chem; 1997 Jan; 40(2):146-67. PubMed ID: 9003514
[TBL] [Abstract][Full Text] [Related]
19. Estrogen to antiestrogen with a single methylene group resulting in an unusual steroidal selective estrogen receptor modulator.
Zhang JX; Labaree DC; Mor G; Hochberg RB
J Clin Endocrinol Metab; 2004 Jul; 89(7):3527-35. PubMed ID: 15240642
[TBL] [Abstract][Full Text] [Related]
20. Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro.
Michael H; Härkönen PL; Kangas L; Väänänen HK; Hentunen TA
Br J Pharmacol; 2007 Jun; 151(3):384-95. PubMed ID: 17420779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]